Metotrexato Pfizer (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, which is essential for producing tetrahydrofolate. This interruption reduces the synthesis of purines and thymidylate, leading to decreased DNA, RNA and protein production. The effect is most pronounced in fast‑dividing cells, such as immune cells and malignant lymphoblasts.

The dosage of Metotrexato Pfizer is individualized by the prescribing clinician based on the specific indication, patient weight, renal function and treatment protocol. Only a qualified health professional can determine the appropriate dose and administration schedule.

Methotrexate is classified as Pregnancy Category X because it is known to cause fetal malformations and embryotoxicity. It is contraindicated in pregnancy and women of childbearing potential must use effective contraception. Breastfeeding is also not recommended while on therapy.

To request Metotrexato Pfizer, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where needed) and import documentation.

Methotrexate is a folate antagonist, whereas other antimetabolites such as 5‑fluorouracil target thymidylate synthase. Methotrexate has a broader therapeutic range, being used for both autoimmune diseases and several cancers, while some alternatives are limited to specific oncology protocols. Safety profiles differ, with methotrexate requiring folic acid supplementation to mitigate mucosal toxicity.

Metotrexato Pfizer should be stored at 2‑8 °C in a refrigerator. Keep the vials in their original packaging, protect them from light, and do not freeze or shake vigorously. If temperature excursions occur, consult the supplier before use.

The product is supplied as a sterile solution for intramuscular, intravenous or intrathecal injection. Administration technique, site selection and infusion rate are determined by the treating physician and nursing staff, following institutional protocols and aseptic guidelines.

Serious risks include bone‑marrow suppression leading to pancytopenia, severe hepatotoxicity that can progress to fibrosis, pulmonary toxicity such as interstitial pneumonitis, and renal impairment from crystal precipitation. Prompt monitoring of blood counts, liver and kidney function is essential to detect these complications early.

Methotrexate is contraindicated in pregnant women, individuals with severe liver disease, uncontrolled infections, and patients with known hypersensitivity to methotrexate or any component of the formulation. Caution is also advised for those with impaired renal function or existing bone‑marrow disorders.